Incanthera (AQSE:INC) FCF Yield % : -3.08 (As of Dec. 15, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Incanthera's Trailing 12-Month Free Cash Flow is £-0.84 Mil, and Market Cap is £27.17 Mil. Therefore, Incanthera's FCF Yield % for today is -3.08%.

The historical rank and industry rank for Incanthera's FCF Yield % or its related term are showing as below:

AQSE:INC' s FCF Yield % Range Over the Past 10 Years
Min: -9.41 Med: 0 Max: 0
Current: -3.08

AQSE:INC's FCF Yield % is ranked better than
73.99% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs AQSE:INC: -3.08

Incanthera's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

Incanthera FCF Yield % Historical Data

The historical data trend for Incanthera's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera FCF Yield % Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Yield %

-7.30

-8.15

-12.68

-9.03

-14.49

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
FCF Yield %	Get a 7-Day Free Trial				-12.64	-10.06	-7.40	-4.25	-25.26

Competitive Comparison of Incanthera's FCF Yield %

For the Biotechnology subindustry, Incanthera's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incanthera's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Incanthera's FCF Yield % falls into.

Incanthera FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Incanthera's FCF Yield % for the fiscal year that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-0.841	/	5.8029237
	=	-14.49%

Incanthera's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-0.733	*	2	/	5.8029237
	=	-25.26%

Incanthera FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Incanthera FCF Yield % Related Terms

Thank you for viewing the detailed overview of Incanthera's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.